1. Clearer FDA Guidance Regarding Inclusion and Exclusion Practices

HVA believes the FDA should provide clearer and more consistent guidance regarding demographic inclusion and exclusion practices within clinical research, including exclusions involving age, sex, gender identity, reproductive or childbearing status, nationality, and other participant characteristics.

Current guidance often allows substantial variation in how research sites and sponsors interpret and apply exclusion criteria, resulting in inconsistent participant experiences and limited transparency regarding why certain groups are excluded from particular studies.

HVA believes additional FDA guidance and standardized expectations may help improve consistency, participant understanding, and transparency regarding demographic eligibility practices within clinical research.

HVA further believes the FDA should require greater transparency regarding the scientific, medical, or safety rationale underlying significant demographic exclusion criteria so that participants can better understand how eligibility decisions are being made and what standards research organizations are expected to follow.

HVA believes clearer disclosure of demographic eligibility rationales within informed consent materials would improve participant understanding, strengthen transparency, promote greater consistency across research organizations, and help support trust and integrity within the clinical research process.

2. Oversight and Accountability for Clinical Research Participant Tracking Systems

HVA believes clinical research participant tracking systems should be subject to clearer regulatory oversight, accountability standards, participant protections, and transparency requirements.

Many healthy volunteers are asked to trust that systems handling sensitive screening, participation, and health-related information are operating in compliance with privacy standards, ethical guidelines, HIPAA-related expectations, and participant protection standards. However, participants often have limited visibility regarding what specific information is being collected, shared, retained, or reported within these systems, as well as how these systems are monitored, audited, regulated, independently reviewed, or held accountable when concerns arise.

Participants may also lack clear reporting pathways or independent oversight resources when concerns involve participant tracking practices, screening restrictions, data retention, information sharing between organizations, delayed status updates, inaccurate information, or the administrative consequences associated with screening-only activity.

HVA believes the FDA should establish clearer oversight expectations, auditing standards, accountability requirements, participant reporting pathways, and review mechanisms applicable to existing and future participant tracking systems utilized within clinical research.

HVA further believes participants should have meaningful opportunities to understand what information is being collected, how long information is retained, how screening activity may affect future eligibility, whether information may be shared across organizations, and what mechanisms exist for requesting clarification or correction of inaccurate records.

HVA further believes that when participant tracking systems, screening restrictions, or clinic policies limit a participant’s ability to pursue other research opportunities during extended screening, admission, or alternate waiting periods, participants should receive clear disclosure regarding those limitations and appropriate compensation for the time, travel, scheduling restrictions, and opportunity loss associated with those expectations.

HVA believes these tracking system practices, screening restrictions, participant protections, reporting pathways, and related compensation policies should be clearly disclosed within informed consent materials so that participants can make fully informed decisions regarding screening and study participation.

HVA further believes greater transparency, accountability, and oversight regarding participant tracking systems would improve participant understanding, reduce confusion regarding screening restrictions and administrative consequences, strengthen trust within the clinical research system, and help support greater consistency, fairness, and integrity across research organizations and participant oversight practices.

3. Clearer FDA Standards Regarding Drug Screening Practices and Participant Exclusion Decisions

HVA believes the FDA should modernize and clarify clinical research standards involving drug screening practices, confirmatory testing procedures, participant notification requirements, and participant protections related to exclusion decisions.

Many healthy volunteers report being excluded, flagged, or permanently restricted from future participation based on preliminary drug screening methods that may be susceptible to false positives associated with legally available medications, supplements, food products, or unintended exposure to certain substances. Participants also report being denied meaningful opportunities for confirmatory testing, clarification, or review before significant exclusion decisions are imposed.

HVA believes current screening practices and preliminary testing methods utilized within some areas of clinical research may not have adequately evolved alongside the growing number of FDA approved medications, supplements, food additives, and commercially available products now known to affect certain preliminary drug screening results.

As the FDA continues to approve and regulate a growing number of over-the- counter medications, supplements, food additives, and commercially available products that may affect preliminary screening results, HVA believes clinical research screening practices and participant protections should appropriately account for these realities.

HVA believes participants should receive clear disclosure regarding:

• The types of drug screening methods utilized

• The limitations of preliminary screening methods

• Whether confirmatory testing is available

• The possible administrative consequences associated with positive or unconfirmed results

• Whether screening results may affect future eligibility or participation opportunities

HVA further believes participants should have meaningful opportunities to review, clarify, and when appropriate challenge inaccurate or unconfirmed screening determinations before significant exclusion decisions are imposed, particularly when those decisions may affect future participation opportunities.

HVA believes the FDA should establish clearer and more modernized standards requiring clinical research organizations to utilize fair, scientifically supportable, and appropriately updated drug screening practices when participant eligibility and future participation opportunities may be significantly affected.

HVA believes these participant advocacy pathways, reporting options, confidentiality protections, participant support resources, and administrative review mechanisms should be clearly disclosed within informed consent materials so that participants can make fully informed decisions regarding study participation and understand what resources are available when concerns arise.

HVA further believes greater transparency, independent participant support pathways, and clearer reporting protections would improve participant understanding, strengthen accountability within clinical research oversight systems, reduce fear of retaliation for reporting concerns, and help support greater trust, integrity, and confidence throughout the clinical research process.

4. Clearer Standards Regarding Participant Compensation Protections

HVA believes the FDA should establish clearer standards and transparency requirements regarding participant compensation protections within clinical research.

Many healthy volunteers report significant time commitments, travel burdens, scheduling restrictions, lost work opportunities, and financial hardship associated with clinical research participation. Participants may spend days or weeks preparing for screening or study admission, arranging transportation, complying with protocol restrictions, or remaining available for participation decisions.

Participants also report situations in which studies are canceled, delayed, overenrolled, or participants are released from participation for reasons unrelated to participant misconduct, including medical, safety, administrative, or sponsor-related decisions beyond the participant’s control

• HVA believes participants should receive clear disclosure regarding

• Compensation policies associated with study cancellation or delay

• Compensation expectations involving alternate status or extended waiting periods

• Compensation policies involving participant removal or early release from participation

• Whether participants will receive partial, prorated, or full compensation under various study-related circumstances

HVA further believes participants should receive fair and proportionate compensation when participation is interrupted, canceled, or terminated for reasons unrelated to participant misconduct or protocol violations.

HVA also believes compensation protections are important to participant safety and research integrity. Participants should not feel pressured to avoid reporting adverse events, symptoms, or safety concerns due to fear of dismissal from participation without reasonable compensation.

HVA believes these compensation policies, financial expectations, participant protections, and circumstances affecting compensation eligibility should be clearly disclosed within informed consent materials so that participants can make fully informed decisions regarding study participation.

HVA further believes greater transparency and clearer standards regarding participant compensation protections would improve participant understanding, strengthen fairness and accountability within clinical research operations, reduce financial hardship and uncertainty for participants, and help support greater trust, integrity, and ethical consistency throughout the clinical research process.

5. Independent Participant Advocacy and Oversight Resources

HVA believes additional FDA oversight and structural reform may be warranted to ensure healthy volunteers have access to meaningful, independent participant advocacy and administrative review pathways within clinical research.

While Institutional Review Boards (IRBs) play an important role in research oversight and participant safety protections, many participant concerns involving administrative disputes, communication failures, staff conduct, discrimination concerns, unexplained exclusion decisions, participant tracking system issues, confidentiality concerns, treatment during studies, sanitary or environmental concerns, and other participant rights issues may fall outside the practical scope of traditional IRB review processes.

Many healthy volunteers report uncertainty regarding where concerns should be directed, what protections are available, whether communications remain confidential, or who is responsible for addressing issues that do not clearly fall within standard IRB reporting categories

HVA believes the FDA should establish clearer standards and oversight expectations regarding independent participant advocacy and administrative review pathways separate from recruitment departments, sponsors, research sites, and traditional IRB functions.

Participants should have access to reasonably independent pathways capable of assisting with participant concerns, reporting guidance, confidentiality questions, administrative disputes, requests for review or correction of inaccurate information, and broader participant protection concerns without fear of retaliation or exclusion from future research participation.

HVA believes the FDA should require clearly identified independent participant advocacy and reporting pathways to be disclosed within informed consent materials, including appropriate contact information, reporting options, confidentiality protections, and explanations regarding the types of participant concerns these pathways are intended to address.

HVA further believes participants should have access to anonymous reporting options and reasonably independent participant support resources separate from recruitment departments, sponsors, research sites, and traditional IRB functions.

HVA believes clearer disclosure and establishment of these participant advocacy pathways within the informed consent process would improve participant understanding, strengthen transparency and accountability, help reduce fear of retaliation or exclusion for reporting concerns, and support greater trust and integrity within the clinical research system for participants, sponsors, research organizations, and oversight bodies alike.

6. Administrative Review and Participant Protection Pathways

HVA believes the FDA should establish clearer oversight expectations and structural protections ensuring healthy volunteers have access to meaningful, independent participant advocacy and administrative review pathways within clinical research.

While Institutional Review Boards (IRBs) play an important role in research oversight and participant safety protections, many participant concerns involving administrative disputes, communication failures, staff conduct, discrimination concerns, unexplained exclusion decisions, participant tracking system issues, confidentiality concerns, treatment during studies, sanitary or environmental concerns, and other participant rights issues may fall outside the practical scope of traditional IRB review processes.

Many healthy volunteers report uncertainty regarding where concerns should be directed, what protections are available, whether communications remain confidential, or who is responsible for addressing issues that do not clearly fall within standard IRB reporting categories.

HVA believes the FDA should require clearly identified independent participant advocacy or administrative review pathways separate from recruitment departments, sponsors, research sites, and traditional IRB functions.

Participants should have access to reasonably independent pathways capable of assisting with participant concerns, reporting guidance, confidentiality questions, administrative disputes, requests for review or correction of inaccurate information, and broader participant protection concerns without fear of retaliation or exclusion from future research participation.

HVA further believes participants should have access to clearly disclosed anonymous or confidential reporting options, as well as meaningful information regarding what types of concerns may be reported through these pathways and what participant protections are available.

7. Standardized Participant Support and Communication Pathways

HVA believes the FDA should establish clearer operational expectations requiring clinical research organizations to maintain accessible participant-support communication pathways separate from standard recruitment functions.

Healthy volunteers consistently report significant communication failures across multiple Phase I research organizations involving unanswered phone calls, unreturned emails, conflicting information, unclear administrative procedures, and the inability to obtain clarification regarding participant concerns unrelated to basic study recruitment.

Many participants report that the only accessible point of contact available at the site level is the recruitment department. However, recruiters are often limited to enrollment-related information and may not have access to administrative records, participant tracking systems, compensation decisions, exclusion determinations, policy clarification, or broader participant-support resources.

As a result, participants frequently report difficulty obtaining accurate information, resolving administrative concerns, correcting inaccuracies, clarifying eligibility decisions, or identifying appropriate escalation pathways when problems arise.

HVA believes clinical research organizations should maintain clearly identified participant-support contacts or participant-support lines accessible by telephone and/or email for participant questions, administrative concerns, clarification requests, reporting guidance, and participant-support issues beyond routine recruitment matters.

HVA further believes participants should receive clear disclosure regarding available participant-support contacts, independent advocacy resources, anonymous reporting pathways when applicable, and IRB contact information so participants can better understand what resources are available and where various concerns should appropriately be directed.

HVA believes these participant-support pathways and communication resources should be clearly disclosed within informed consent materials and participant-facing study materials so that participants can make fully informed decisions and have meaningful access to communication and support resources throughout the clinical research process.

HVA further believes clearer participant communication standards and accessible participant-support pathways would improve transparency, reduce confusion and administrative frustration, strengthen accountability within clinical research operations, and help support greater participant trust, fairness, and confidence throughout the clinical research system.